| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00033033 | Cocaine-Related Disorders|Substance-Related Disorders | Drug: Reserpine | National Institute on Drug Abuse (NIDA)|Cincinnati VA Medical Center | Phase 2 | 2001-07-01 | 2017-01-11 |
| NCT00267657 | Amphetamine-Related Disorders | Drug: Reserpine | National Institute on Drug Abuse (NIDA) | Phase 1 | 2004-01-01 | 2017-01-10 |
| NCT02684786 | Pulmonary Artery Hypertension | Drug: reserpine|Procedure: stellate ganglion block|Drug: lidocaine | Mayo Clinic | Phase 1 | 2016-03-01 | 2016-02-17 |
| NCT00000514 | Cardiovascular Diseases|Cerebrovascular Disorders|Heart Diseases|Hypertension | Drug: chlorthalidone|Drug: atenolol|Drug: reserpine | National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA) | Phase 3 | 1984-06-01 | 2016-04-14 |
| NCT00015106 | Cocaine-Related Disorders | Drug: Lamotrigine | National Institute on Drug Abuse (NIDA) | Phase 2 | 1997-11-01 | 2017-01-11 |
| NCT00000499 | Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases | Drug: chlorthalidone|Drug: reserpine|Drug: hydralazine|Drug: metoprolol | National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA) | Phase 2 | 1980-09-01 | 2013-11-25 |
| NCT00362804 | Schizophrenia|Schizoaffective Disorder | Drug: Tetrabenazine | Centre for Addiction and Mental Health|Stanley Medical Research Institute | | 2002-02-01 | 2012-07-04 |
| NCT01108029 | Parkinson's Disease|Gait Disorders, Neurologic | Drug: memantine|Drug: placebo | University Hospital, Lille | Phase 4 | 2009-10-01 | 2012-03-23 |
| NCT00684489 | Hypertension | Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.|Drug: renin guided therapeutics-no specific med. Any anti-hypertensive med. | Medical University of South Carolina|New York Presbyterian Hospital | | 2003-09-01 | 2008-05-22 |
| NCT00000620 | Atherosclerosis|Cardiovascular Diseases|Hypercholesterolemia|Hypertension|Diabetes Mellitus, Type 2|Diabetes Mellitus|Coronary Disease | Drug: Anti-hyperglycemic Agents|Drug: Anti-hypertensive Agents|Drug: Blinded fenofibrate or placebo plus simvastatin | National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute on Aging (NIA)|National Eye Institute (NEI)|Centers for Disease Control and Prevention | Phase 3 | 1999-09-01 | 2016-11-21 |
